Xoran Technologies Completes Phase 1 for their Mobile Lung CT Scanner

Xoran Technologies LLC is the leading innovator in compact, specialized medical CT scanners. They’ve pioneered the design and testing of low-dose radiation, cone beam CT scanners which are optimized for the patient’s point-of-care.

Xoran has just announced the successful completion of Phase 1 for their NHLBI (National Heart, Lung, and Blood Institute) grant for their mobile lung CT. This grant had been provided to support the company in their mission to commercialize their future open-bore CT products.

“This truly mobile device helps to support the diagnosis, triaging, and monitoring of the lungs of respiratory patients both in the intensive care unit, and in future respiratory pandemic situations,” explains Misha Rakic, Xoran’s CEO.

Along with the NHLBI grant, the company collaborated with doctors at the University of Michigan to expand the applications for their point-of-care imaging technology. 

With their xCAT IQ™—an FDA 510k-cleared mobile CT system for bone and brain imaging, Xoran has shown capability in point-of-care CT solutions for the neuro intensive care unit (NICU) and the operating room. This new project allows Xoran to optimize a point-of-care solution specifically for lung imaging. The combined Xoran and University of Michigan team aims to develop a highly deployable CT scanner intended for use in ICU, especially for patients with acute respiratory failure requiring mechanical ventilation.

Doctors are often limited in their diagnostic capabilities based on the equipment available. They may make clinical decisions based on chest X-rays which can be limited in the information they can convey. Robert Dickson, MD, Associate Professor—Pulmonary & Critical Care Medicine, Associate Professor—Microbiology & Immunology, and a clinical collaborator, all at the University of Michigan says, “Our patients are often too sick to transport down to radiology, or they have a communicable disease like COVID-19 that we don’t want to spread around the hospital. A bedside scanner would have immediate impact in how we manage our sickest patients.”

Are you developing new pharmaceuticals for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts